Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-CD19-PBD-conjugate-ADC, Immunoglobulin g1-kappa, anti-(homo sapiens b-lymphocyte antigen cd-19)chimeric monoclonal antibody conjugated to an average of two molecules of tesirine.gamma.1 heavy chain (1-449) (mus musculus vh (ighv1-69*02 (86%) (ighd)-ighj4*01)) (8.8.13) (1-120) -, Lonca + [10] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), DNA modulators(DNA modulators), DNA alkylating agents + [1] |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (23 Apr 2021), |
RegulationAccelerated assessment (US), Conditional marketing approval (EU), Orphan Drug (EU), Priority Review (CN), Accelerated Approval (US) |
Molecular FormulaC42H65N5O17 |
InChIKeyNPTPHNNPPOZTSM-GSSDHLSPSA-N |
CAS Registry- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11338 | Loncastuximab tesirine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diffuse large B-cell lymphoma recurrent | NO | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | LI | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | IS | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | EU | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | NO | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | IS | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | EU | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | LI | 20 Dec 2022 | |
Diffuse Large B-Cell Lymphoma | US | 23 Apr 2021 | |
High grade B-cell lymphoma | US | 23 Apr 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Large B-cell lymphoma | NDA/BLA | CN | 08 Jun 2023 | |
Large B-cell lymphoma | NDA/BLA | CN | Overland PharmaceuticalsStartup | 08 Jun 2023 |
Diffuse large B-cell lymphoma refractory | Phase 3 | HU | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CA | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CH | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | IL | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | JP | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CN | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | PR | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | GB | 16 Sep 2020 |
NCT05296070 (ASH2024) Manual | Phase 2 | 22 | (qveqckyrmu) = aiknyflpea kwwxlsamha (dwrimeownl ) View more | Positive | 08 Dec 2024 | ||
NCT04998669 (ASH2024) Manual | Phase 2 | 39 | (nwooatyojj) = kjjiwswlck gkgiknmeed (fxtvribgpz ) View more | Positive | 07 Dec 2024 | ||
(Patients with POD24) | (nwooatyojj) = dxfmvezqsa gkgiknmeed (fxtvribgpz ) View more | ||||||
Not Applicable | - | (wxdrrqyfma) = xwjhyasicd jzznsvgpsv (rocpzudtaq ) View more | - | 04 Sep 2024 | |||
Chimeric Antigen Receptor T-cell Therapy | (wxdrrqyfma) = oddbbhbzdp jzznsvgpsv (rocpzudtaq ) View more | ||||||
NCT05296070 (Biospace) Manual | Phase 2 | 50 | (qcqmgqeqev) = ivyplziheq igrcfloset (qppspfesng ) | Positive | 07 May 2024 | ||
Phase 2 | 145 | (xuxzeizrrd) = hnzvafeoza nxmlmcvbqn (pxkpbyydrw, 50.0 - 81.0) View more | Positive | 01 Apr 2024 | |||
Phase 1/2 | 136 | (Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib) | btihrllihb(ohuocuutsa) = zwxjppbsah leqslaflgm (ejqvpvmerd, xekrpzqpic - niwotkvynj) View more | - | 06 Feb 2024 | ||
(Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib) | btihrllihb(ohuocuutsa) = kaqgwmncxp leqslaflgm (ejqvpvmerd, kvasrmzpbd - ppwaqpzcxn) View more | ||||||
Not Applicable | Diffuse Large B-Cell Lymphoma Third line | 81 | (who received CAR-T at 2L/lonca at 3L) | (bbddzyjrac) = dzhouopust klleuqkana (fctumehpct ) View more | Positive | 01 Feb 2024 | |
Loncastuximab Tesirine3L/lonca at 4L | (bbddzyjrac) = qoycndbswz klleuqkana (fctumehpct ) View more | ||||||
GlobeNewswire Manual | Not Applicable | - | (tacetsjcbc) = cirxebvrke qxrowqxgzo (rdmcjgxkui ) View more | Positive | 04 Jan 2024 | ||
LOTIS-7 (GlobeNewswire) Manual | Phase 1 | - | (znfqihwwrt) = The dose-limiting toxicity (DLT) period has been cleared for the first dosing level of ZYNLONTA 90 µg/kg in both arms, oufikxrwvy (krtkcsaaag ) | Positive | 04 Jan 2024 | ||
Phase 2 | 64 | (ufspzuberl) = msckdqanjj oeuppqifzn (sukloaasyw, 38.7 - 64.2) View more | Positive | 11 Dec 2023 |